Table 1. Characterization of extended-spectrum β-lactamase-producing Escherichia coli (ESBLECs) and their antimicrobial resistance patterns.
Horse No. | Sampling location | β-lactamase genes | Antimicrobial resistance patterna | Phylogenetic group | Code of isolateb (n=24) |
---|---|---|---|---|---|
24 | Mihod | blaCTX-M-2 | ABPC, CEZ, CTX, SM, OTC, TC | A | ac |
blaTEM-1, blaCTX-M-2 | ABPC, CEZ, CTX, SM, OTC, TC, TM | A | b | ||
34 | Miho | blaTEM-1, blaCTX-M-2 | ABPC, CEZ, CTX, TM | B2 | ac |
blaTEM-1, blaCTX-M-2 | ABPC, CEZ, CTX, SM, TM | B2 | b, c | ||
39 | Miho | blaTEM-1, blaCTX-M-2 | ABPC, CEZ, CTX, SM, TM | B1 | ac, b |
47 | Miho | blaCTX-M-2 | ABPC, CEZ, CTX, SM, OTC, TC, TM | B1 | ac, b |
55 | Miho | blaCTX-M-2 | ABPC, CEZ, CTX | D | ac |
blaCTX-M-2 | ABPC, CEZ, CTX, OTC, TC | D | b | ||
68 | Miho | blaCTX-M-2 | ABPC, CEZ, CTX, TM | A | ac |
78 | Miho | blaCTX-M-2 | ABPC, CEZ, CTX | B2 | ac, b |
107 | Ritto | blaCTX-M-2 | ABPC, CEZ, CTX, SM | B1 | ac |
116 | Ritto | blaTEM-1, blaCTX-M-2 | ABPC, CEZ, CTX, SM, TM | B2 | ac, b |
blaTEM-1, blaCTX-M-2 | ABPC, CEZ, CTX, TM | B2 | c | ||
130 | Ritto | blaCTX-M-2 | ABPC, CEZ, CTX, SM, TM | A | ac, b |
131 | Ritto | blaCTX-M-2 | ABPC, CEZ, CTX | B2 | ac |
blaCTX-M-2 | ABPC, CEZ, CTX, OTC, TC | B1 | bc | ||
144 | Ritto | blaCTX-M-2 | ABPC, CEZ, CTX, SM, TM | B1 | ac, b |
aABPC, ampicillin; CEZ, cefazolin; CTX, cefotaxime; SM, streptomycin; TC, tetracycline; OTC, oxytetracycline; TM, trimethoprim. Antimicrobial suscaptibility test was interpreted using CLSI criteria and JVARM report. bOne or more isolates were confirmed as ESBLEC from one sample. cThirteen selected donor isolates in conjugation assay; donor isolate per sample was considered based on phylogenetic group analysis. dMiho, Miho Training Center, Japan Racing Association, Ibaraki; Ritto, Ritto Training Center, Japan Racing Association, Shiga.